Bacteriotherapy for inflammatory bowel disease: therapeutic tool and/or pharmacological vectors? - Université Pierre et Marie Curie Accéder directement au contenu
Article Dans Une Revue Gastroentérologie Clinique et Biologique / Research and Clinics in Hepatology and Gastroenterology Année : 2009

Bacteriotherapy for inflammatory bowel disease: therapeutic tool and/or pharmacological vectors?

Résumé

Inflammatory bowel diseases are the result of an abnormal immune response to environmental factors including the intestinal microbiota. Epithelial and immune cells of the intestinal mucosa recognise specific bacterial molecules via Toll like and NOD like receptors and this interaction modulates the inflammatory response (activation of the NF-kappaB pathway). It is thus rational to try treatments which could modify the intestinal microbiota i.e. antibiotics, new substrates (prebiotics) or new micro-organisms (probiotics). We review the literature on existing evidence for the efficacy of probiotic strains or combinations in patients with pouchitis (good evidence), ulcerative colitis (fair evidence), and Crohn's disease (no evidence at the present time). We also discuss the mechanisms of action, the use of microbial agents as pharmacological vectors, the development of genetically modified probiotics (including a clinical pilot trial in patients with Crohn's disease), and safety issues.

Domaines

Chimie organique
Fichier non déposé

Dates et versions

hal-00816363 , version 1 (22-04-2013)

Identifiants

Citer

P. Marteau, H. Sokol, X. Dray, P. Seksik. Bacteriotherapy for inflammatory bowel disease: therapeutic tool and/or pharmacological vectors?. Gastroentérologie Clinique et Biologique / Research and Clinics in Hepatology and Gastroenterology, 2009, 33 Suppl 3, pp.S228-34. ⟨10.1016/S0399-8320(09)73158-6⟩. ⟨hal-00816363⟩
25 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More